Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Lung Cancer

Free Subscription Articles published in Lancet Oncol Retrieve available abstracts of 31 articles: HTML format Text format

Single Articles

January 2012
1. ROSELL R , Carcereny E, Gervais R, Vergnenegre A, et al
   Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
   Lancet Oncol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
2. CIULEANU T , Stelmakh L, Cicenas S, Miliauskas S, et al
   Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
   Lancet Oncol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   November 2011
3. PIRKER R , Pereira JR, von Pawel J, Krzakowski M, et al
   EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
   Lancet Oncol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
4. METZE K
   Pitfalls in the assessment of prognostic factors.
   Lancet Oncol. 2011;12:1095-6.
   PubMed     Text format     Related articles   
   
   
   
   
5. LEVEQUE D
   Pharmacokinetics of gefitinib and erlotinib.
   Lancet Oncol. 2011;12:1093.
   PubMed     Text format     Related articles   
   
   
   
   October 2011
6. QUOIX E , Ramlau R, Westeel V, Papai Z, et al
   Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.
   Lancet Oncol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   September 2011
7. GOVINDAN R
   Hope without hype: EML4-ALK inhibition for treatment of lung cancer.
   Lancet Oncol. 2011.
   PubMed     Text format     Related articles   
   
   
   
   
8. SHAW AT , Yeap BY, Solomon BJ, Riely GJ, et al
   Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
   Lancet Oncol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   August 2011
9. RINALDI F , George E, Clark P
   NICE guidance on erlotinib for the maintenance treatment of non-small-cell lung cancer.
   Lancet Oncol. 2011;12:728-30.
   PubMed     Text format     Related articles   
   
   
   
   
10. STINCHCOMBE TE , Der CJ
    Are all KRAS mutations created equal?
    Lancet Oncol. 2011;12:717-8.
    PubMed     Text format     Related articles   
    
    
    
    July 2011
11. MITSUDOMI T
    Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?
    Lancet Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
12. ZHOU C , Wu YL, Chen G, Feng J, et al
    Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
    Lancet Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
13. O'BYRNE KJ , Gatzemeier U, Bondarenko I, Barrios C, et al
    Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
    Lancet Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. YASUDA H , Kobayashi S, Costa DB
    EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.
    Lancet Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
15. YOUNG R , Hopkins R, Etzel C, El-Zein R, et al
    Genetics of lung cancer susceptibility and COPD.
    Lancet Oncol. 2011;12:622-3.
    PubMed     Text format     Related articles   
    
    
    
    June 2011
16. VENTO S , Lanzafame M
    Tuberculosis and cancer: a complex and dangerous liaison.
    Lancet Oncol. 2011;12:520-2.
    PubMed     Text format     Related articles   
    
    
    
    May 2011
17. BURKI T
    Cancer mortality in Northern Ireland.
    Lancet Oncol. 2011;12:428.
    PubMed     Text format     Related articles   
    
    
    
    March 2011
18. SENIOR K
    Explaining trends in lung cancer deaths in women.
    Lancet Oncol. 2011;12:220.
    PubMed     Text format     Related articles   
    
    
    
    February 2011
19. PAO W , Girard N
    New driver mutations in non-small-cell lung cancer.
    Lancet Oncol. 2011;12:175-80.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2011
20. WEN C , Dehnel T
    China wrestles with lung cancer.
    Lancet Oncol. 2011;12:15.
    PubMed     Text format     Related articles   
    
    
    
    
21. PERRONE F
    Cetuximab in NSCLC: another trial needed.
    Lancet Oncol. 2011;12:3-4.
    PubMed     Text format     Related articles   
    
    
    
    December 2010
22. GATZEMEIER U , von Pawel J, Vynnychenko I, Zatloukal P, et al
    First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.
    Lancet Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
23. THUN MJ
    Early landmark studies of smoking and lung cancer.
    Lancet Oncol. 2010;11:1200.
    PubMed     Text format     Related articles   
    
    
    
    October 2010
24. BRENNAN P , Hainaut P, Boffetta P
    Genetics of lung-cancer susceptibility.
    Lancet Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2010
25. YANG P , Jen J, Li Y, Wang L, et al
    GPC5 rs2352028 variant and risk of lung cancer in never smokers - Authors' reply.
    Lancet Oncol. 2010;11:716.
    PubMed     Text format     Related articles   
    
    
    
    
26. HANDEL AE , Ramagopalan SV
    GPC5 and lung cancer in multiple sclerosis.
    Lancet Oncol. 2010;11:714.
    PubMed     Text format     Related articles   
    
    
    
    
27. LANDI MT , Chatterjee N, Caporaso NE, Rotunno M, et al
    GPC5 rs2352028 variant and risk of lung cancer in never smokers.
    Lancet Oncol. 2010;11:714-6.
    PubMed     Text format     Related articles   
    
    
    
    July 2010
28. PIRKER R
    Bevacizumab in lung cancer: hurdles in clinical development.
    Lancet Oncol. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
29. CRINO L , Dansin E, Garrido P, Griesinger F, et al
    Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.
    Lancet Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
30. STINCHCOMBE TE , Govindan R
    One more fallen star--ZODIAC and its implications.
    Lancet Oncol. 2010;11:604-5.
    PubMed     Text format     Related articles   
    
    
    
    
31. SIPAHI I , Debanne SM, Rowland DY, Simon DI, et al
    Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.
    Lancet Oncol. 2010;11:627-36.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: